May 9, 2001 — HILDEN, Germany — Biotechnology company Qiagen GmbH plans to construct a new five-story building which will include production facilities for biological products and synthesis processes.
The QIAGEN subsidiary has selected M+W mZander to engineer the $12.4 million facility that will be an addition to the company’s existing Hilden, Germany site. The project should be completed during summer 2002.
The facility will also include laboratories and a quality control center.
QIAGEN is a Dutch holding company with subsidiaries in Germany, the US, the UK, Switzerland, France, Italy, Australia and Canada. The company specializes in products for the handling, separation, purification and amplification of nucleic acid as well as equipment for molecular biological automation, synthetic nucleic acid and related services.